ClinicalTrials.gg
CompletedNCT04397887Updated May 21, 2020

Seminal TEX101 as a Predictor of Recovery of Spermatogenesis in Azoospermic Men With Palpable Varicocele

An interventional study of micro-surgical varicocelectomy in Azoospermia, Nonobstructive and Varicocele, sponsored by Cairo University. Completed at 1 site in Egypt. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-05-21.

Sponsored by Cairo University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2019, registered May 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The aim of the study is to assess if seminal TEX 101 can predict the restoration of spermatogenesis and appearance of sperms in the ejaculate after micro-surgical varicocelectomy among azoospermic patients.

Read the detailed description

Male patients (40) cases attending the outpatient clinic of Andrology at KASR EL-AINI university hospitals, all patients presented with azoospermia, age:18-43 years, complaining mainly of infertility or accidently discovered azoospermia during premarital check-up or chronic testicular pain caused by longstanding varicocele. Infertile Non Obstructive Azoospermia (NOA) (n=40) subjected to varicocelectomy and patients evaluated 3 months after varicocelectomy by semen analysis, then according to results population divided into 2 groups: Group A (Responders): Patients with positive semen analysis for

sperms 3 months after varicocelectomy.

Group B (Non Responders): Patients with no sperms in semen analysis

in 3 and/or 6 months after varicocelectomy.

Method of Estimation of human TEX101 in semen:

A 1 ml collected semen samples were centrifuged for 20 minutes at 1000xg at 4 o C, then supernatant of each sample was collected for estimation of TEX101. The human TEX101 (Testis expressed 101) was assayed by commercially available ELISA kit supplied by Wuhan Fine Biotech Co., Ltd. China.

Principle of the procedure:

This kit was based on sandwich enzyme-linked immune-sorbent assay technique. Anti- TEX101 antibody was pre-coated onto 96-well plate. The biotin conjugated antibody was used as detection antibodies. The standards, test samples and biotin conjugated detection antibody were added to the wells subsequently, and washed with wash buffer.

HRP-Streptavidin was added and unbound conjugates were washed away with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The intensity of yellow is proportional to the target amount of sample captured in plate.

02

Conditions studied

  • Azoospermia, Nonobstructive
  • Varicocele

Keywords

  • Varicocele
  • Azoospermia
  • TEX 101
03

In context

Azoospermia, Nonobstructive

23 studies on the registry are indexed under Azoospermia, Nonobstructive; 7 are open to participants now.

This study's enrollment of 40 is below the median of 61 across 12 interventional studies indexed under Azoospermia, Nonobstructive.

Browse Azoospermia, Nonobstructive studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Azoospermia in at least 2 separate semen analyses
  • Palpable varicocele

Exclusion criteria

Exclusion Criteria:

  • Obstructive azoospermia
  • Abnormal Karyotype
  • Previous chemotherapy, radiotherapy and or diagnosed maligancy.
  • previous testicular of inguinal surgeries.
  • secondary azoospermia
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Men with Azoospermia and varicocele

    In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods

    Procedure: micro-surgical varicocelectomy

Interventions

  • Proceduremicro-surgical varicocelectomy

    Sub-inguinal micro-surgical varicocelectomy

06

What researchers measure

Primary outcomes

  1. Sperm retrieval in ejaculate

    finding sperms in the ejaculate

    Time frame: 3 months follow-up

  2. Sperm retrieval in ejaculate

    finding sperms in the ejaculate

    Time frame: 6 months follow-up

07

Study locations

1 site
  • Andrology department, Faculty of Medicine - Cairo University
    Cairo, 12622, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Apr 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 21, 2020
StartActual
Jan 1, 2019
Primary completionActual
Apr 30, 2020
CompletionActual
Apr 30, 2020
Last update
May 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04397887
Lead sponsor
Cairo University
Responsible party
Mohamed Wael Ragab (Andrology consultant/ lecturer, Cairo University) — Principal investigator
First posted
May 21, 2020
Start date
Jan 1, 2019
Primary completion
Apr 30, 2020
Completion
Apr 30, 2020
Last update
May 21, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion